1	Category of paper: Original Article		
2	Article title: Risk factors for bacterial infections in patients with moderate to severe COVID-19: A		
3	case control study		
4			
5	N. Nasir ¹ , F. Rehman ¹ , S.F. Omair ¹		
6	¹ Dept. of Medicine, Aga Khan University, Karachi, Pakistan		
7			
8			
9	Corresponding Author		
10	Nosheen Nasir FRCP (Edin), FCPS (IM)FCPS (ID), MSc		
11	Assistant Professor, Dept. of Medicine		
12	Aga Khan University, Stadium Road, Karachi 74800, Pakistan		
13	Email: <u>Nosheen.nasir@aku.edu</u>		
14	Phone: +922134864574 Fax: +922134932095		
15			
16	Running Title: Bacterial Infections in patients with COVID-19		
17	Funding: No funding was available for this study		
18	None of the authors have any conflict of interest		
19			
20			

21 ABSTRACT

22 **Objective**

Bacterial infections are known to complicate respiratory viral infections and are associated with adverse outcomes in COVID-19 patients. A case control study was conducted to determine risk factors for bacterial infections where cases were defined as moderate to severe/critical COVID-19 patients with bacterial infection and those without were included as controls. Logistic regression analysis was performed.

28 Results

Out of a total of 50 cases and 50 controls, greater proportion of cases had severe or critical 29 30 disease at presentation as compared to control i.e 80% vs 30% (p<0.001). Hospital acquired 31 pneumonia (72%) and Gram negative organisms (82%) were predominant. Overall antibiotic utilization was 82% and was 64% in patients who had no evidence of bacterial infection. The 32 median length of stay was significantly longer among cases compared to controls (12.5 versus 7.5 33 days) (p=0.001). The overall mortality was 30%, with comparatively higher proportion of deaths 34 35 among cases (42% versus 18%) (p=0.009). Severe or critical COVID-19 at presentation (AOR: 4.42 times; 95% CI; 1.63-11.9) and use of steroids (AOR: 4.60; 95% CI 1.24-17.05) were independently 36 associated with risk of bacterial infections. These findings have implications for antibiotic 37 stewardship as antibiotics can be reserved for those at higher risk for bacterial superinfections. 38

39 Key words

40 Bacteria ; COVID-19; nosocomial infections; co-infection.

41 INTRODUCTION

COVID-19 pandemic has claimed more than 1,000,000 lives to date and its long term impact is yet 42 to be determined. Respiratory viral infections have been well known to predispose patients to co-43 44 infections and these lead to increased disease severity and mortality as was observed in 1918 45 influenza outbreak, where most mortalities were due to simultaneous bacterial infection.[1] 46 Bacterial co-infection also led to poor outcome in 2009H1N1 influenza pandemic.[2] The incidence of bacterial co-infection in COVID-19 ranges from 3-30% [3, 4]. Zhou and colleagues 47 showed that in the current coronavirus disease 2019 (COVID-19) pandemic, 50% of patients who 48 49 died, had secondary bacterial infections, while another study showed presence of both bacterial 50 and fungal infection [5, 6]. Due to similar clinical phenotype and difficulties in identifying COVID-51 19 disease from atypical bacterial pneumonia or nosocomial pneumonia some guidelines advise 52 empirical antibiotics [7]. In a study conducted at 38 hospitals in Michigan 56.6% patients received empirical antibiotics therapy[8]. 53 54 Studies indicate that bacterial co-infection and secondary infection complicate COVID-19 though 55 regional data is scarce[6]. Moreoverrisk factors for these infections need to be better elucidated.

Antimicrobials are used empirically which may lead to antimicrobial resistance in the long term. Hence, it is imperative to conduct comparative studies to identify those COVID-19 patients who are candidates for empirical antibiotic therapy and curtail widespread injudicious use of antibiotics.The purpose of this study is to determine the risk factors of bacterial infections in patients and characterization of these infections along with the sensitivity patterns of isolated organisms in patients presenting with moderate to severe/critical COVID-19.

62 MAIN TEXT

63 METHODS

A case control study was conducted from February 2020 to June 2020 at a tertiary care center in Karachi, Pakistan. Cases were defined as patients who had PCR confirmed moderate to severe/critical COVID-19 as per WHO criteria for severity and had evidence of bacterial infection based on isolation of bacteria in any of the culture specimens collected during admission along with symptoms and signs consistent with infection. Controls were defined as patients who had PCR confirmed moderate to severe/critical COVID-19 as per WHO criteria for severity but who did not develop bacterial infection during admission.

71 All adult patients (age >=18 years) hospitalized with moderate and severe/critical COVID-19 as per 72 WHO definition for severity [9] at Aga Khan University Hospital, Karachi were assessed for presence of bacterial co-infection at admission as well as followed for secondary bacterial 73 74 infection during hospitalization. Patients with signs and symptoms consistent with bacterial 75 infection during hospitalization with COVID-19 at various sites such as urinary tract infection, 76 hospital acquired pneumonia, ventilator associated pneumonia, central line associated blood-77 stream infection etc. as defined by CDC [10] and who were identified to have growth of significant 78 bacteria in the respective appropriate culture specimens (e.g. urine, tracheal aspirate, blood from central line etc) collected during admission were included whereas those patients who had 79 evidence of bacterial infection on culture but did not have signs and symptoms consistent with 80 infection at any site as defined by CDC [10] were considered to be colonized and excluded from 81 study and patients with mono-microbial fungal infections were also excluded. 82

Patients who had any positive bacterial culture were identified from infection control records and 83 84 were screened for eligibility criteria for cases. Controls were identified from medical records among all moderate to severe/critical COVID-19 admissions. A sample size of 50 cases was obtained. For 85 each case patient, 1:1 control patient(s) was also obtained (50 controls). Main outcome variable was 86 87 presence of bacterial infection defined as infection with clinically significant bacteria which is identified from a culture specimen among those with moderate or severe/critical COVID-19. 88 Exposure variables included patient related factors such as age in years, gender, comorbidities, type 89 90 of ward/unit to which patient was admitted, presence of invasive devices and immunosuppression received. We collected data on potential confounders including previous co-morbids and severity of 91 illness. Data was collected on structured proforma which was pretested for one week at the start of 92 the study. Patients were further stratified as having community-onset infection if they had culture 93 94 specimen positive within 72 hours of admission and hospital-onset infection if they were found to 95 have a bacterial infection after 72 hours of hospitalization. Bacteriological identification was performed in College of American Pathologists (CAP) certified Clinical Microbiology laboratory at Aga 96 97 Khan University by conventional methods. Antibiotic susceptibility of isolated bacteria was evaluated by the standard disc diffusion method in accordance with the Clinical & Laboratory Standards 98 Institute (CLSI) recommendations. 99

100 Statistical analysis

Frequencies with percentages were reported for categorical variables such as gender, type of infection by site, etc. according to case or control status. For continuous variables such as age, length of stay etc. median and interquartile range were reported by case and control status. Logistic regression analysis was performed to determine the association between risk factors and

- bacterial infection in moderate and severe/critical COVID-19 patients and the results were
 reported as adjusted odds ratios with 95% confidence intervals. P-value 0.05 was considered
 significant. Data was analyzed using Stata version 12.
- 108 The study received an exemption from ethical approval from the Aga Khan University Ethics
- 109 Review Committee (ERC reference number: 2020-5178-14123).

110 **RESULTS**

A total of 50 cases and 50 controls were included in the analysis after making relevant exclusions 111 over a period of 4 months from February to June 2020. Median age of cases was 58 years (IQR) 112 and of controls was 62 years (IQR). The overall male to female ratio was 2.8 and gender 113 distribution was similar between the groups. The most frequent co-morbids were diabetes and 114 115 hypertension in both groups. The severity of illness was significantly different in both the groups 116 with a high proportion (80%) of severe/critical COVID-19 patients among cases compared to 30% 117 in controls (p<0.001). Among those COVID-19 patients with bacterial infections, the majority (72%) 118 was hospital-acquired and 28% were community-acquired at onset and the commonest site of 119 infection was hospital-acquired pneumonia (Figure 1). Nine out of 50 had bacteremia. Gram-120 negative infections were more common (82%) than gram-positive infections. The most frequently 121 isolated organism from sputum specimens was multi-drug resistant Acinetobacter species in 27%, 122 followed by multi-drug resistant *Pseudomonas aeroginosa* in 25% (Figure 2). Among patients with 123 community-acquired infections, the most common organism was Staphylococcus aureus (5/14) in which four were methicillin-resistant and extended spectrum beta lactamase producing (ESBL) 124 125 Klebsiella pneumoniae in (9/14). Majority of patients had a mono-microbial infection (70%). Seven 126 out of 50 patients had simultaneous infection at two sites.

Among laboratory investigations, the median C-reactive protein and median neutrophil to 127 128 lymphocyte ratio were significantly higher in cases compared to controls (Table 1). However, there was no statistically significant difference between procalcitonin levels in COVID-19 patients with 129 bacterial infection compared to those without bacterial infection (p=0.883). With regard to the 130 131 unit of admission, COVID-19 patients with bacterial infections were more frequently admitted to the Intensive care unit (56%) compared to patients without bacterial infections who were mostly 132 133 admitted to the ward (38%) (p<0.001). The use of invasive devices such as endotracheal tube and 134 central venous catheters were also more frequent among cases compared to controls (p<0.001)(Table 1). Patients with bacterial infections were managed with invasive ventilation in 56% of 135 cases compared to 14% controls (p<0.001) and with non-invasive ventilation in 64% of cases 136 compared to 34% controls (p=0.003). Comparatively higher proportion of patients who had 137 138 bacterial infections had received treatment with systemic steroids (92%) (p=0.001). All patients 139 with bacterial infections had received antibiotics and among controls (32/50) had received antibiotics. The choice of empiric antibiotics was based on local antibiogram and institutional 140 guidelines for community acquired pneumonia and definitive antibiotic treatment was decided 141 based on identification and sensitivity pattern of the isolated organism. The overall mortality was 142 143 30%. Patients with COVID-19 having bacterial infections had a comparatively greater proportion of 144 deaths (42% versus 18%) (p=0.009). Out of 21 patients who died, 18 had infection with gram negative organism with Acinetobacter sp (n=9) and *Pseudomonas aeroginosa* (n=7) being most 145 146 common isolates. The median length of stay was also significantly longer among cases compared to controls (12.5 versus 7.5 days) (p=0.001). Multivariable logistic regression showed that patients 147 148 who were severe to critically ill at the time of admission with COVID-19 were 4.42 times (95% Cl;

1.63-11.9) at risk for bacterial infection and treatment with steroids was also a significant risk
factor (AOR: 4.60; 95% Cl 1.24-17.05). Admission to ward unit was found to be protective (OR:
0.15; 95% Cl 0.02-0.75).

152 DISCUSSION

153 Our study found that there is a significant association of severity of illness with COVID-19 at presentation and treatment with steroids with the development of superimposed bacterial 154 infection. Our patient cohort had moderate to severe or critical COVID-19 at the time of 155 156 hospitalization and we had excluded patients who had specimen positive with contaminants or 157 who were presumed to be colonized and without clinically significant infection. There was a high male to the female ratio and several studies have reported a greater risk of severe illness with 158 159 COVID-19 in males compared to females [11, 12]. We had very few community-acquired infections 160 and the majority were hospital-acquired. This is similar to study conducted by Hughes et al. from UK where only 3.2% co-infections were reported [13] and a study from Spain describing the 161 incidence of co-infections [14]. This was also confirmed in a meta-analysis where the reported 162 prevalence of co-infections was 3.5% [15]. Majority of the patients in our cohort developed 163 164 hospital acquired infections. This is consistent with other reported literature [15, 16]. The most 165 common site of infection was pneumonia and this is in concordance with initial reports from China [16]. Gram-negative infections have dominated as far as the type of organisms is concerned and 166 this is similarly seen in studies reported from other parts of the world describing superinfections 167 or secondary bacterial infections [14, 16]. There is a lack of reported literature on the sensitivity 168 169 patterns of organisms isolated. In our study, we found multi-drug resistant Acinetobacter as the 170 predominant pathogen causing hospital acquired infections and methicillin resistant

Staphylococcus aureus as the main cause of co-infection in COVID-19 in our patients. A case series 171 of 19 patients from Iran has described Acinetobacter baumanii in majority of patients requiring 172 ICU admission[17] which reflects epidemiological similarity to Pakistan. In our study, the overall 173 174 mortality was 30% and was higher in those who had bacterial infections. This is also consistent 175 with data reported from Europe and parts of Asia [15, 18]. Moreover, we found that overall antibiotic utilization was 82% and was 64% in patients who had no evidence of bacterial infection. 176 177 This has also been similarly reported [18] indicating widespread injudicious use of antibiotics 178 which can potentiate the problem of antimicrobial resistance. In our study, we did not find procalcitonin to be a reliable marker of distinguishing patients who had bacterial infections and 179 180 those who did not have bacterial infections. Although studies have described procalcitonin levels to remain normal in severe COVID-19, whether they increase in bacterial infections has not been 181 182 reported and indicates need of large comparative studies exploring this relationship[19]. Our 183 study is the first comparative study with regard to bacterial infections in the setting of moderate and severe to critical COVID-19 and describes the sensitivity pattern of organisms in addition to 184 clearly classifying them into community and hospital acquired infections. 185

186 Conclusions

Our study highlights need for improving antibiotic stewardship practices and reserving antibiotics for those who are severely ill with COVID-19 at presentation and require treatment with systemic steroids and provides insight into the lack of utility of serum procalcitonin as a marker of bacterial sepsis in this setting.

191 LIMITATIONS

- 192 Our study is limited as it's a single center experience which might affect generalizability.
- 193 Moreover, we did not have molecular methods and genotyping available for our bacterial isolates
- and information on the isolation rate of the prevalent Gram negatives and MRSA in non-COVID-19
- 195 patients over the study period was not available to draw comparisons with rates of infection seen
- in COVID-19 patients.

198 **List of Abbreviations:**

IQR	Interquartile range
ERC	Ethics review committee
ESBL	Extended-spectrum Beta -lactamase
C-RP	C-reactive protein
COVID-19	Coronavirus infection disease-19
MDR	Multi-drug resistant
MRSA	Methicillin-resistant Staphylococcus aureus

199 **DECLARATIONS**

200 Ethics approval and consent to participate

- 201 The study was submitted for ethical approval to the Aga Khan University Ethics review committee
- and received exemption (ERC reference number: 2020-5178-14123). Consent to participate was
- 203 not required because there was no direct interaction with participants. The study was eligible for
- 204 exemption as data was collected from records and no personal identifiers were recorded or used.
- 205 **Consent for publication**
- 206 Not applicable

207 Availability of data and materials

208 All data generated or analysed during this study are included in this published article

209 Competing interests

210 The authors declare that they have no competing interests

211 Funding

212 No funding was obtained for this study.

213 Authors' contributions

- 214 NN conceived idea, major contributer to manuscript, collected and analyzed data
- 215 FR conceived idea, contributed to manuscript, collected data
- 216 FU collected data and contributer to manuscript
- 217 All authors read and approved the manuscript
- 218 Acknowledgements
- 219 Not applicable

220 **REFERENCES**

221 1. Taubenberger JK, Morens DM. The 1918 influenza pandemic and its legacy. Cold Spring Harbor perspectives in medicine. 2020;10(10):a038695. 222 223 Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller III RR, et al. Critical illness from 2009 2. 224 pandemic influenza A (H1N1) virus and bacterial co-infection in the United States. Critical care medicine. 225 2012;40(5):1487. 226 3. Clancy CJ, Nguyen MH. COVID-19, superinfections and antimicrobial development: What can we 227 expect? Clinical Infectious Diseases. 2020. 228 Lehmann CJ, Pho MT, Pitrak D, Ridgway JP, Pettit NN. Community acquired co-infection in COVID-4. 229 19: a retrospective observational experience. Clinical Infectious Diseases. 2020. 230 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult 5. 231 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020. 232 6. Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and 233 fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial 234 prescribing. Clinical Infectious Diseases. 2020. 235 7. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review 236 and meta-analysis. Journal of Infection. 2020. 237 Vaughn VM, Gandhi T, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric antibacterial 8. 238 therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-239 hospital cohort study. Clinical Infectious Diseases. 2020. 240 Organization WH. Clinical management of COVID-19: interim guidance, 27 May 2020. World Health 9. 241 Organization; 2020. 242 Control CfD. CDC/NHSN Surveillance Definitions for Specific Types of Infections 2020 [Available 10. 243 from: https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf. 244 Stall NM, Wu W, Lapointe-Shaw L, Fisman DN, Giannakeas V, Hillmer MP, et al. Sex- and Age-11. 245 Specific Differences in COVID-19 Testing, Cases, and Outcomes: A Population-Wide Study in Ontario, 246 Canada. J Am Geriatr Soc. 2020;68(10):2188-91. 247 Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL. Sex Differences in Case Fatality Rate of 12. 248 COVID-19: Insights From a Multinational Registry. Mayo Clin Proc. 2020;95(8):1613-20. 249 Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among 13. 250 hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clinical 251 Microbiology and Infection. 2020;26(10):1395-9. 252 14. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. 253 Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective 254 cohort study. Clinical Microbiology and Infection. 255 15. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-256 infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. 257 Clinical Microbiology and Infection. 2020. 258 He Y, Li W, Wang Z, Chen H, Tian L, Liu D. Nosocomial infection among patients with COVID-19: A 16. 259 retrospective data analysis of 918 cases from a single center in Wuhan, China. Infection control and 260 hospital epidemiology. 2020;41(8):982-3. 261 17. Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation 262 of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infectious 263 Diseases. 2020;20(1):646. 264 Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy III R, et al. Bacterial 18. 265 infections and patterns of antibiotic use in patients with COVID-19. Journal of Medical Virology.n/a(n/a).

- 266 19. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A
- 267 meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2020;505:190-1.

268

Table 1: Comparison of moderate and severe COVID-19 patients with and without bacterial

271 infections

Variables	All (N=100)	COVID-19 with	COVID-19	p-
		bacterial	without	value
		infection (n=50)	bacterial	
			infection (n=50))
Median age in years (IQR)	60 (52-70)	58 (49-67)	62 (54-70)	0.512
Sex				
Male	74 (74%)	39 (78%)	35 (70%)	0.362
Female	26 (26%)	11 (22%)	15 (30%)	
Co-morbids				
Diabetes	56 (56%)	27 (54%)	29 (58%)	0.687
Hypertension	55 (55%)	25 (50%)	30 (60%)	0.315
Ischemic heart disease	28 (28%)	13 (26%)	15 (30%)	0.656
Chronic kidney disease	17 (17%)	9 (18%)	8 (16%)	0.79
COPD	3 (3%)	2 (4%)	1 (2%)	
Severity of illness				<0.001
Moderate	43 (43%)	10 (20%)	33 (66%)	
Severe	57 (57%)	40 (80%)	17 (34%)	

Laboratory Investigations				
Median C-Reactive Protein mg/L	147.47 (48.5 –	169.34 (95.86-	81.57 (34.36-	0.009
(IQR)	199.64)	231.19)	197.19)	
Median Neutrophil to	6.20 (3.29-11.12)	8.58 (5.41-14.66)	4.28 (2.96-7.89)	0.001
lymphocyte ratio (IQR)				
Median Procalcitonin ng/ml (IQR)	0.25 (0.107-0.6)	0.369 (0.15-1.78)	0.14 (0.07-0.44)	0.883
Type of Ward				
ICU Admission	37 (37%)	28 (56%)	9 (18%)	<0.001
SCU Admission	42 (42%)	20 (40%)	22 (44%)	0.685
Ward admission	21 (21%)	2 (4%)	19 (38%)	<0.001
Presence of invasive devices				
Endotracheal tube	37 (37%)	28 (56%)	7 (14%)	<0.001
CVP	39 (39%)	29 (58%)	10 (20%)	<0.001
Treatment				
Invasive ventilation	35 (35%)	28 (56%)	7 (14%)	< 0.001
Non-invasive ventilation	49 (49)	32 (64%)	17 (34%)	0.003
Antibiotics	82 (82%)	50 (100%)	32 (64%)	<0.001

	aa (aaa ()	10 (0 (0 ())	(2.2	
Tocilizumab	29 (29%)	18 (36%)	11 (22%)	0.123
Systemic steroids	77 (77%)	46 (92%)	31 (62%)	0.001
0.4				
Outcomes				
Length of stay [median (IQR) days	9 (6-14)	12.5 (7-18)	7.5 (4-11)	0.001
Dead	30 (30%)	21 (42%)	9 (18%)	0.009
Discharged	70 (70%)	29 (58%)	41 (82%)	

273

Figure 1: Sites of Infection in moderate and severe COVID-19 patients with bacterial infections





- 278 Figure 2: Clinically significant isolates from culture specimens in patients with moderate and
- 279 severe COVID-19
- 280

